Table 2.
Ongoing PD-1 MAb combination trials in MBC.
| Study phase | Immunotherapy type | Other therapies | Breast cancer type | Clinicaltrials.org number |
|---|---|---|---|---|
| PD-1 | ||||
| I | Nivolumab | Nab-paclitaxel ± gemcitabine or carboplatin | MBC, pancreatic cancer, and NSCLC | NCT02309177 |
| II | Nivolumab | Cabozantinib (MET inhibitor) | TN-MBC | NCT03316586 |
| Ib/II | Pembrolizumab | Eribulin | TN-MBC | NCT02513472 |
| II | Pembrolizumab | Carboplatin | MBC | NCT03213041 |
| II | Pembrolizumab | Anthracycline or endocrine therapy | HR+ and TN-MBC | NCT02648477 |
| II | Pembrolizumab | Nab-paclitaxel | TN-MBC | NCT02752685 |
| Expl. | Pembrolizumab | Nab-paclitaxel and carboplatin | TN-MBC | NCT03121352 |
| II | Pembrolizumab | Eribulin | HR+ MBC | NCT03051659 |
| II | Pembrolizumab | Cyclophosphamide | TN-MBC | NCT02768701 |
| II | Pembrolizumab | With carboplatin versus carboplatin alone | Chest wall breast cancer | NCT03095352 |
| II | Pembrolizumab | Capecitabine | TN-MBC | NCT03044730 |
| Expl. | Pembrolizumab | Paclitaxel | HR+ and TN-MBC | NCT03018080 |
| II | Pembrolizumab | IBC | NCT02411656 | |
| II | Pembrolizumab with | Vorinostat and tamoxifen | HR+ MBC | NCT02395627 |
| II | Pembrolizumab | Chemotherapy | TNBC | NCT02734290 |
| II | Pembrolizumab | Carboplatin and gemcitabine | TN-MBC | NCT02755272 |
| II | Pembrolizumab | XRT | TN-MBC | NCT02730130 |
| II | Pembrolizumab | Imprime PGG | TN-MBC and metastatic melanoma | NCT02981303 |
| II | Pembrolizumab | BRCA-mutated MBC | NCT03025035 | |
| II | Pembrolizumab | XRT | HR+ MBC | NCT03051672 |
| II | Pembrolizumab | Selective androgen receptor modulator (SARM) GTX-024 | TN-MBC | NCT02971761 |
| II | Pembrolizumab | Abemaciclib | HR+ MBC | NCT02779751 |
| Ib | Pembrolizumab | TDM1 | HER2+ MBC | NCT03032107 |
| II | Pembrolizumab | BGB324 | TN-MBC or LABC | NCT03184558 |
| II | Pembrolizumab | Letrozole and palbociclib | HR+ MBC | NCT02778685 |
| I/II | Pembrolizumab | Binimetinib | TN-MBC or LABC | NCT03106415 |
| I | Pembrolizumab | JAK2 inhibition | TNBC | NCT03012230 |
| II | Pembrolizumab | BGB324 | TN-MBC or LABC | NCT03184558 |
| II | Pembrolizumab | Letrozole and palbociclib | HR+ MBC | NCT02778685 |
Abbreviations: IBC, inflammatory breast cancer; LABC, locally advanced breast cancer; MBC, metastatic breast cancer; NSCLC, non–small-cell lung cancer; TNBC, triple-negative breast cancer; TN-MBC, triple-negative metastatic breast cancer.